Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: An update from the German Hodgkin's Lymphoma Study Group (GHSG).

被引：0
|
作者：
Schulz, H
Rehwald, U
Reiser, M
Ruediger, T
Morschhauser, F
Diehl, V
Engert, A
机构：
[1] Univ Cologne, Dept Internal Med 1, D-5000 Cologne 41, Germany
[2] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[3] Ctr Hosp Reg & Univ Lille, F-59037 Lille, France
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3066
引用
收藏
页码：775A / 775A
页数：1
相关论文
共 50 条
  • [21] Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
    Sieniawski, M.
    Reineke, T.
    Josting, A.
    Nogova, L.
    Behringer, K.
    Halbsguth, T.
    Fuchs, M.
    Diehl, V.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1795 - 1801
  • [22] OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG)
    Borchmann, S.
    Mueller, H.
    Haverkamp, H.
    Baues, C.
    Markova, J.
    Huettmann, A.
    Glunz, A.
    Fuchs, M.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 5 - 6
  • [23] Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
    Boell, Boris
    Goergen, Helen
    Arndt, Nils
    Meissner, Julia
    Krause, Stefan W.
    Schnell, Roland
    von Tresckow, Bastian
    Eichenauer, Dennis A.
    Sasse, Stephanie
    Fuchs, Michael
    Behringer, Karalin
    Klimm, Beate C.
    Naumann, Ralph
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4431 - +
  • [24] Prognostic factors in intermediate stage Hodgkin's disease: A retrospective analysis from the German Hodgkin Lymphoma Study Group (GHSG).
    Schiller, P
    Pfistner, B
    Reineke, T
    Paulus, U
    Engert, A
    Wolf, J
    Diehl, V
    BLOOD, 2002, 100 (11) : 772A - 773A
  • [25] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
    Josting, A
    Franklin, J
    May, M
    Koch, P
    Beykirch, MK
    Heinz, J
    Rudolph, C
    Diehl, V
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 221 - 230
  • [26] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [27] Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)
    Eichenauer, Dennis A.
    Fuchs, Michael
    Pluetschow, Annette
    Klimm, Beate
    Halbsguth, Teresa
    Boell, Boris
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2011, 118 (21) : 1166 - 1167
  • [28] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [29] Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group
    Wiedenmann, S
    Schiller, P
    Paulus, U
    Wolf, J
    ANNALS OF ONCOLOGY, 2002, 13 : 84 - 85
  • [30] Hodgkin's lymphoma in elderly patients:: A comprehensive retrospective analysis from the German Hodgkin's Study Group
    Engert, A
    Ballova, V
    Haverkamp, H
    Pfistner, B
    Josting, A
    Dühmke, E
    Müller-Hermelink, K
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5052 - 5060
12345